Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Information source: New York University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alzheimer's Disease
Intervention: memantine (Drug); Placebo (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: New York University School of Medicine Official(s) and/or principal investigator(s):
Lidia Glodzik, MD PhD, Principal Investigator, Affiliation: NYU School of Medicine
Summary
Recent data show that marked cell damage precedes the clinical manifestation of Alzheimer's
disease (AD). Hence, targeting populations at risk with pharmacological interventions is a
possible strategy to lessen the burden of the disease. Cognitively normal individuals with
subjective memory complaints (SMC) manifest biological characteristics consistent with early
AD and are at risk for future cognitive decline. Family history of AD also constitutes a
risk. In a previous study the investigators showed that memantine slows down the
accumulation of phosphorylated tau in normal SMC subjects. Using a multivoxel high field MR
spectroscopy (MRS) technique, the investigators also demonstrated that memantine decreased
hippocampal glutamate. Both these findings may be consistent with the drug's
anti-excitotoxic activity. In this new project the investigators propose to treat a sample
of 12 presymptomatic individuals at risk (SMC and family history of AD) with memantine. This
will be a double blind, placebo controlled study with a control group (12 non-treated
subjects). The investigators will determine whether the effects of memantine as assessed by
cognitive performance and MRS are present after 4 months of treatment and persist 2 months
after discontinuation. MRS will be used to evaluate the effect of memantine on levels of the
neurotransmitter glutamate and neuronal viability marker N-acetylaspartate (NAA) in the
hippocampus. The investigators will test the following hypotheses:
1. In subjects with SMC, memantine has modifying effects on brain biochemistry as
reflected in MRS reductions in glutamate (reduced excitotoxicity) and increases in NAA
(neuronal integrity).
2. The effects of the drug persist (as a marker of sustained neuroprotection) and can be
measured 2 months after discontinuation of the treatment.
Clinical Details
Official title: Effects of Memantine on the Magnetic Resonance Spectroscopy (MRS) Measures of Neuronal Integrity in Subjects at Risk for Alzheimer's Disease
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Primary outcome: N-acetylaspartate
Eligibility
Minimum age: 55 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- presence of subjective memory complaints without objective evidence of impaired
cognition
- family history of Alzheimer's disease
Exclusion Criteria:
- major depression
- Parkinson's disease
- stroke
- seizures
- uncontrolled diabetes or hypertension
- current benzodiazepine use
- substance abuse
- contraindication for MRI
- contraindications for memantine
Locations and Contacts
NYU School of Medicine, Dept. of Psychiatry, Center for Brain Health, New York, New York 10016, United States
Additional Information
Starting date: July 2009
Last updated: October 20, 2014
|
